CareDx, Inc. (CDNA)
Nasdaq · Healthcare · Diagnostics & Research
$69.85+4.02%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.6B
- P/E (trailing)
- 33.6
- Forward P/E
- 54.1
- 52-week range
- $13.95 – $70.75
- 52-week change
- +357.74%
- EPS (trailing)
- $2.08
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $380M (+13.79%)
- Net income
- −$21.4M
- Operating margin
- −8.1%
- Diluted EPS
- −$0.40
From the company’s annual report on SEC EDGAR.
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software.
Headquarters: Brisbane, United States · 761 employees · caredx.com